Physician profile
Jared Steven Kramer
NPI 1134105463
$41,194.37
in general payments reported to CMS, 2019-2025
38 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $768 · 2021: $830 · 2022: $796 · 2023: $703 · 2024: $6,723 · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $3,183 · Travel and Lodging: $2,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,682.13 |
| Food and Beverage | $3,183.29 |
| Travel and Lodging | $2,941.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36,081.81 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,246.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $603.69 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $447.29 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $335.97 | 2019-2025 | |
| Astellas Pharma US INC | $272.78 | 2022-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $243.07 | 2019-2020 | |
| Mylan Specialty L.P. | $232.39 | 2019-2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $220.83 | 2019-2025 | Spravato |
| Abbvie INC. | $191.10 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.82 | 2019-2024 | Tradjenta, Synjardy, Jardiance |
| Sanofi-Aventis U.S. LLC | $152.06 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $141.33 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $135.03 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.99 | 2022-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.